Design Therapeutics Inc (DSGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -69,792 | -49,588 | -66,862 | -63,308 | -35,533 |
| Depreciation Amortization | -2,631 | -5,602 | -5,547 | -990 | 52 |
| Other Working Capital | 3,110 | -993 | 728 | 1,992 | 1,396 |
| Other Operating Activity | 14,955 | 13,078 | 13,121 | 10,989 | 4,708 |
| Operating Cash Flow | $-54,358 | $-43,105 | $-58,560 | $-51,317 | $-29,377 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 23,106 | 44,295 | 52,792 | -220,108 | -52,106 |
| PPE Investments | -193 | -340 | -256 | -879 | -1,538 |
| Investing Cash Flow | $22,913 | $43,955 | $52,536 | $-220,987 | $-53,644 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 25,738 | 513 | 724 | 662 | 254,499 |
| Other Financing Activity | 0 | 0 | 0 | -427 | 124,712 |
| Financing Cash Flow | $25,738 | $513 | $724 | $235 | $379,211 |
| Beginning Cash Position | 22,563 | 21,200 | 26,500 | 298,569 | 2,379 |
| End Cash Position | 16,856 | 22,563 | 21,200 | 26,500 | 298,569 |
| Net Cash Flow | $-5,707 | $1,363 | $-5,300 | $-272,069 | $296,190 |
| Free Cash Flow | |||||
| Operating Cash Flow | -54,358 | -43,105 | -58,560 | -51,317 | -29,377 |
| Capital Expenditure | -193 | -340 | -256 | -918 | -1,538 |
| Free Cash Flow | -54,551 | -43,445 | -58,816 | -52,235 | -30,915 |